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CI therapy is effective in patients with relatively good levels of residual arm function but its
applicability to patients with low-functioning hemiparesis is not entirely clear. In the present
study, we examined the feasibility and efficacy of the CI therapy concept in patients with
very limited upper arm function prior to treatment, and further tested how the length
of daily shaping training and constraining the good arm affects treatment outcome. In
a baseline-controlled design, 65 chronic patients were treated with 2 weeks of modified
CI therapy. Patients were randomly allocated to four treatment groups receiving 90 or
180 min of daily shaping training applied with or without constraint, respectively. Outcome
was measured through the Reliable Change Index, which was calculated for parameters
of motor function, health, and psychological wellbeing. Follow-up data were collected at 6
and 12 months.Two analyses were conducted, a whole-group analysis across all 65 partic-
ipants and a sub-group analysis contrasting the four treatment variants. The whole-group
analysis showed a significant treatment effect, which was largely sustained after 1 year.
The sub-group analysis revealed a mixed picture; while improvements against the baseline
period were observed in all four subgroups, 180 min of daily shaping training coupled with
the constraint yielded better outcome on the MAL but not the WMFT, while for 90 min
of training the level of improvement was similar for those who wore the constraint and
those who did not. Together these results suggest that, at least in those patients available
for follow-up measures, modified CI therapy induces sustained improvements in motor
function in patients with chronic low-functioning hemiparesis. The absence of clear differ-
ences between the four treatment variants points to a complex relationship between the
length of daily shaping training and the constraint in this patient group, which is likely to
be mediated by fatigue and/or compliance with the constraint.
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INTRODUCTION
Eighty-five percent of stroke survivors sustain upper limb hemi-
paresis (1). Several systematic reviews [e.g. Ref. (2, 3)] suggest that
constraint-induced movement therapy (CI therapy), and modified
versions thereof, achieve sustained improvements of upper limb
function. While the evidence-base for CI therapy is strong, it is
primarily relevant to patients with relatively good levels of resid-
ual recovery, with Taub himself estimating that about 20–25%
of patients meet the minimum motor criteria for participation
in the signature CI therapy intervention (4). This confinement to
patients with relatively good residual recovery is one of the barriers
to the implementation of CI therapy into clinical practice (5, 6).
The focus of rehabilitation research on patients with better resid-
ual hand function is not unique to CI therapy, but reflects a trend
in contemporary motor rehabilitation research (7, 8). Generally,
treatment options for patients with poorer recovery are limited
and the available evidence base is relatively weak (9, 10).
CI therapy is theoretically grounded and proposes tangible
treatment mechanisms. It is designed to deliver improved motor
function as well as changes in habitual motor behavior. The lat-
ter is achieved (i) through intensive paretic arm training, (ii)
constraining the non-paretic arm, and (iii) by considering the
psychological aspects of the treatment process (11, 12). Because
of these credentials, the CI therapy concept is worthy of further
exploration in more severely affected patients. However, its appli-
cation in patients with limited residual ability poses challenges. For
example, when residual ability is poor, everyday activities become
very difficult, if not impossible, when the non-paretic arm is con-
strained. Patients might, therefore, struggle to maintain the level
of independence that they are accustomed to while undergoing
the CI therapy intervention. Moreover, by forcing the use of the
paretic arm while restricting the non-paretic arm, the intervention
is likely to expose the coping mechanisms and avoidance behav-
iors patients may have adopted in response to their compromised
abilities. One might, therefore, argue that the constraint condition
forces patients to confront their disability in a rather harsh way,
and hence question the appropriateness of its use. On the other
hand, evidence suggests that the constraint is an effective tool in
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fostering real-world treatment benefit (4), which may well out-
weigh its negative aspects and hence warrant, if not mandate its
use. Investigating the feasibility of constraining the non-paretic
hand, and the treatment benefit it promotes, is therefore required.
Another aspect of the CI therapy application in less well-
recovered patients is that of treatment intensity. Previous studies
have demonstrated that treatment regimes with longer training
intervals induce greater benefit (13). However, it is also conceiv-
able that longer training times might be less effective if patients
become fatigued and tired. Protocols with shorter daily training
sessions might, therefore, be equally or even more effective than
longer training sessions in patients with greater motor limitations.
There is a wealth of literature on CI therapy and related pro-
tocols [e.g., Ref. (2, 3, 14, 15)]. However, to the best of our
knowledge few published studies have attempted to apply CI ther-
apy to patients not fulfilling the minimum motor criteria specified
by the CI therapy signature intervention, and none have exam-
ined directly the benefit of constraining the non-paretic arm in
relation to treatment intensity. Based on our previous work (16),
the present study, therefore, examined the effects of non-paretic
arm constraint (constraint vs. no constraint) and amount of daily
training (180 vs. 90 min), as well as their interaction. Similar
to the CI therapy signature intervention, a treatment contract
was employed to ensure compliance and engagement. Treatment
effects were determined through measures of motor function (pri-
mary outcomes), as well as healthy and psychological wellbeing
(secondary outcomes).
METHODS
PARTICIPANTS
Patients were recruited via local general practitioners (GPs), self-
help groups, and newspaper advertisements. Eighty-two patients
with first-ever stroke and chronic hemiplegia for a minimum
of 1 year were screened. Sixty-five of these participants (mean
age was 54.4± 1.5 years; 38 male and 27 female; 36 left and
29 right hemiparesis; chronicity= 4.3± 0.4 years with range= 1–
14.9 years) participated in the study and complete the actual treat-
ment phase. Due to drop outs, the N reduced to 34 at the 6-months
follow-up and 23 at the 12-months follow-up (see Figure 1 for
summary). Patients were recruited on the basis of the presentation
of their motor deficits rather than lesion location. Confirmation
of a unilateral thalamic or cortical stroke was obtained from the
GP, but no specific lesion information was available to us.
Low-functioning hemiparesis was defined as a minimum motor
criterion comprising the ability to produce a voluntary movement
with any part of the hand, a finger, or the wrist no matter how
small. Patients who met or exceeded Taub’s criterion of 20° wrist
and 10° finger extension were excluded. Further exclusion criteria
comprised seizures 6 months prior to participation, frequent falls,
severe aphasia, a history of major secondary medical or mental
health conditions, and a Mini-Mental State Score<24. All patients
were community dwelling and lived either with family or a carer.
The study took place in a laboratory housed at the School of
Psychology within the University of Surrey. The study protocol was
approved by the NHS Surrey Research Ethics Committee and the
Ethics Committee of the University of Surrey. Written informed
consent and GP assent were obtained prior to participation.
INTERVENTION
Patients were randomly allocated to four versions of modified
CI therapy (13, 16, 17), comprising daily training of either 180
or 90 min per day (Tx180 or Tx90) and the presence or absence
of the constraint (C or nC, respectively), resulting in the groups
Tx90 C (N = 18), Tx90 nC (N = 19), Tx180 C (N = 14), and Tx180
nC (N = 14; see Table 1 for demographic details). Patients were
consecutively allocated to the groups in the order of intake. Ran-
domization was not blinded. Treatment was provided daily for 10
consecutive days spread over a fortnight.
The paretic arm training used the principles of shaping training
(12), with tasks individually adapted to accommodate the patients’
level of ability. Training was complemented by a treatment con-
tract, brief daily problem solving sessions, and a diary in which
patients noted the use of the constraint (if applicable) and their
activities outside the treatment setting.
Patients in the two constraint groups (Tx90C, Tx180C) were
asked to wear the constraint at home as specified in the treat-
ment contract. The latter was tailored to participants’ ability, and
defined situations in which the constraint could be worn safely.
This was reviewed at the beginning of every session as motor ability
improved, or as difficulties arose.
TESTING PROCEDURE
A baseline-controlled cross-over design with five time points was
used: baseline (two weeks prior to treatment), pre (start of treat-
ment), post (end of treatment), and follow-up measures at 6 and
12 months (Fup6, Fup12). In these testing sessions, data on motor
function and psychological wellbeing were acquired through a
range of tests comprising the Frenchay Arm Test [FAT (18)], an
adapted version of the graded version of the Wolf Motor Func-
tion Test [WMFT (19); http://www.uab.edu/citherapy/images/
pdf_files/CIT_Training_WMFT_Manual.pdf ], the Nine-Hole Peg
Test [NHPT (20)], and the Motor Activity Log [MAL (21)]. In the
same sessions, data on general health and psychological wellbeing
were acquired using the Short Form 36 [SF36 (22)], Stroke Impact
Scale [SIS (23)], Hospital Anxiety and Depression Scale [HADS
(24)], and Visual Analog Mood Scale [VAMS (25)]. Further details
of the tests are provided in the legend of Table 2 as well as in the
Supplementary Materials.
ANALYSIS AND STATISTICS
Demographic data were analyzed for the factor TREATMENT
GROUP using one-way ANOVAs or chi-square tests as appro-
priate.
For the main analysis of primary and secondary outcome, lon-
gitudinal treatment benefits were evaluated through the reliable
change index approach [RCI (26, 27)]. This measure determined
the standard error of difference from the variation in outcome
indices from baseline to pre-therapy interval. The standard error
of difference is used in RCI analysis as a measure of baseline fluc-
tuation from which reliable, significant change during and after
the treatment phase can be calculated. This method is described
in detail in the Supplementary Materials; the raw scores are listed
in Table S2 in Supplementary Material.
For each outcome measure, RCI was calculated for the ther-
apy interval (Pre-post; termed treatment effect in the manuscript),
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Flow Diagram:
Enrolled (n= 65)
Assessed for eligibility (n= 82)
Excluded (n= 17)
Not meeting inclusion criteria (n= 16)
Declined to participate (n= 1)
Other reasons (n= 0)
Analysed: (n= 18)
Tx90 C
(n= 18)
Tx180 nC
(n= 14)
Allocation
Whole Group
Analysis
N=65 (Pre- vs
Post- Treatment)
Enrollment
Tx180 C
(n= 14)
Tx90 nC
(n= 19)
Analysed: (n= 19) Analysed: (n= 14) Analysed: (n= 14)
Subgroup Analysis
N = 34
Tx90 C
n=10
(lost: n= 8)
Tx180 nC
n=8
(lost: n= 6)
Tx180 C
n=8
(lost: n= 6)
Tx90 nC
n=10
(lost: n= 9)
6 month follow--up
Whole Group
Analysis
N=34
(6 month Fup)
Whole Group
Analysis
N=23
(12 month Fup)
N = 23
12 month follow--up
Tx90 C
n=7
(lost: n= 3)
Tx180 nC
n=6
(lost: n= 2)
Tx180 C
n=4
(lost: n= 4)
Tx90 nC
n=6
(lost n= 4)
FIGURE 1 | Summary of the trial and group allocation. Note that
(1) all patients received the allocated treatment, (2) the n for “patients
lost” refers to the number of participants having completed the MAL,
(3) for attending the follow-up did not necessarily completed all tests;
a full breakdown of n per test is given in the supplementary materials,
and (4) the cause for drop out were difficulties/unwillingness to
traveling to the University (many patients had come from further
afield).
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and for changes over the follow-up period between post ther-
apy and 6 months after therapy (Post-Fup6), and between 6 and
12 months post therapy (Fup6-Fup12). In this way, treatment effect
expressed as RCI represents a measure of significant change with
treatment corrected for baseline fluctuations; while follow-up mea-
sures the longevity of these treatment effects in relation to baseline
fluctuations.
The RCI scores were subsequently analyzed in two ways. Firstly,
to test whether the CI therapy concept improved motor func-
tion in the chronic state, a whole-group analysis across all 65
participants was conducted using one-sample t -tests (versus zero,
representing no reliable change). To examine, the relative differ-
ence between the four treatment variants factorial 2× 2 ANOVAs
with CONSTRAINT condition (C/nC) and TRAINING INTEN-
SITY (T180/T90) were calculated for each outcome parameter,
respectively. Effect sizes were calculated using Cohen’s d for the
Table 1 | Demographic characteristics or the treatment groups.
Therapy Constraint N Age Gender
(M/F)
Hemiparesis
(L/R)
Chronicity
(years)
Tx90 N 19 55.8±2.6 7/12 12/7 4.5±0.8
Y 18 57.3±2.6 12/6 10/8 4.4±0.6
Tx180 N 14 56.4±3.1 10/4 9/5 3.4±0.9
Y 14 46.9±3.5 9/5 5/9 4.6±1.2
65 54.4±1.5 38/27 36/29 4.3±0.4
Gender (M/F), male/female; hemiparesis (L/R), side (Left/Right) of hemiparetic
limb; chronicity, time since stroke.
whole-group analysis and eta squared (η2p) for sub-group analysis.
Eta squared was used in the ANOVA analysis to determine the
proportion of variance in outcome measure attributed to the
each therapy modification. Effect sizes were categorized using
the following criteria of small (d = 0.2; η2p = 0.01), medium
(d = 0.5; η2p = 0.06), and large (d = 0.8; η2p = 0.14). Because
of large drop out in the follow-up period, the follow-up analysis
was only sensibly for the whole-group since as the cell size became
too small for the sub-group analysis. However, for completion, the
sub-group analysis is made available in Table S1 in Supplementary
Materials).
Finally, the association between primary (motoric) and sec-
ondary (health and psychological wellbeing) outcomes after CI
therapy was explored through regressions between the treatment
effect RCIs for the primary outcome measures (FAT, WMFT,
NHPT, MAL; primary outcome measures) and treatment effect
RCIs of the secondary outcome measures (SIS, SF36, HADS,
VAMS).
The results below will first summarize the findings for the group
level including treatment effect and follow-up, followed by the
sub-group analysis (treatment effect only) and correlations.
RESULTS
DEMOGRAPHIC DATA
There were no significant differences between the four treat-
ment groups in terms of baseline WMFT-FA [F(3,56)= 1.2,
p= 0.3], FAT [F(3,56)= 0.2, p= 0.9], side of hemiparesis [χ2
(3, N = 65)= 3.1; p= 0.4], chronicity [F(3,64)= 0.3, p= 0.8],
gender [χ2 (3, N = 65)= 5.3; p= 0.2], and age [F(3,64)= 2.5,
p= 0.07]. The patients were also evenly distributed between
Table 2 | Summary table for whole-group analysis statistics.
Test Pre-post Post-Fup6 Fup6-Fup12
FAT t =3.7(64), p<0.001, d =0.61 t =−1.7(30), p<0.095, d =0.31 t =1.2(18), p<0.2, d =0.28
WMFT TT t =−2.9(64), p<0.01, d =0.35 t =0.7(30), p<0.5, d =0.12 t =−1.5(19), p<0.1, d =0.34
WMFT FA t =8.0(64), p<0.001, d =0.99 t =0.5(30), p<0.9, d =0.03 t =3.1(19), p<0.007, d =0.68
MAL AoU t =9.6(64), p<0.001, d =1.19 t =−2.4(33), p<0.025, d =0.4 t =−0.3(22), p<0.8, d =0.06
MAL QoM t =11.1(64),p<0.001, d =1.38 t =−1.8(33), p<0.07, d =0.32 t =−0.5(22), p<0.6, d =0.11
NHPT S t =4.4(62), p<0.001, d =0.46 t =−0.2(29), p<0.8, d =0.04 t =0.8(18), p<0.4, d =0.18
NHPT L t =1.6(63), p<0.1, d =0.2 t =0.9(29), p<0.4, d =0.17 t =0.4(18), p<0.7, d =0.1
SIS Tot t =6.4(63), p<0.001, d =0.8 t =1.4(32), p<0.2, d =0.25 t =−1.1(22), p<0.3, d =0.23
SIS Phys t =7.0(63), p<0.001, d =0.87 t =0.8(32), p<0.5, d =0.13 t =−1.6(22), p<0.1, d =0.32
SF36 P t =0.8(60), p<0.4, d =0.11 t =1.9(31), p<0.074, d =0.33 t =−0.9(21), p<0.4, d =0.2
SF36 M t =0.7(60), p<0.5, d =0.09 t =1.9(31), p<0.071, d =0.33 t =0.02(21), p<0.99, d <0.01
HADS A t =−2.4(60), p<0.05, d =0.30 t =−2.3(30), p<0.032, d =0.4 t =1.8(20), p<0.084, d =0.4
HADS D t =−0.6(60), p<0.6, d =0.08 t =−2.9(30), P<0.007, d =0.52 t =0.6(20), p<0.6, d =0.13
VAMS P t =0.9(59), p<0.4, d =0.12 t =1.4(31), p<0.2, d =0.26 t =−0.4(21), p<0.7, d =0.09
VAMS N t =0.5(59), p<0.6, d =0.06 t =−0.1(31), p<0.9, d =0.02 t =0.7(21), p<0.5, d =0.15
Gray boxes highlight significant changes.
The acronyms are as follows: FAT, Frenchay Arm Test; WMFT FA, Wolf Motor Function Test Functional Ability; WMFT TT, Wolf Motor Function Test Time Taken; MAL
AoU, Motor Activity Log Amount of Use; MAL QoM, Motor Activity Log Quality of Movement; NHPT S, Nine-Hole PegTest Small; NHPT L, Nine-Hole PegTest Large;
SIS Tot, Stroke Impact Score Total; SIS Phys, Stroke Impact Score Physical subscale; SF36, Short Form 36; HADS A, Hospital Anxiety and Depression Scale Anxiety
subscore; HADS D, Hospital Anxiety and Depression Scale Depression subscore; VAMS, Visual Analog Mood Score with VAMS, P, positive; and VAMS N, negative.
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groups such that there were equal proportions wearing a constraint
in the 90 and 180 min therapy groups, and equal numbers with
the greatest training intensity in the constraint and no constraint
groups [χ2 (1, N = 65)= 0.1; p= 0.9].
WHOLE-GROUP ANALYSIS
Treatment effect
The primary outcome measures indicated significant improve-
ments in motor function (Figure 2) with large effects on
both MAL scales [AoU: t (64)= 9.6, p< 0.001, d = 1.19; QoM:
t (64)= 11.1, p< 0.001, d = 1.38], and WMFT-FA [t (64)= 8.0,
p< 0.001, d = 0.99], as well as a medium sized effect on the FAT
[t (64)= 3.7, p< 0.001, d = 0.61], and small-to-medium effects on
the NHPT_S [t (62)= 4.4; p< 0.001, d = 0.46], and the WMFT-
TT [t (64)=−2.9, p= 0.01, d = 0.35] An improvement of small
effect size was found for the NHPT_L, but this effect did not reach
significance [t (63)= 1.6, p= 0.1, d = 0.2].
For the secondary outcomes improvements (Figure 3) were
demonstrated by large effects on the physical subscale of the
SIS [t (63)= 7.0, p< 0.001, d = 0.87] and the overall SIS score
[t (63)= 6.4, p< 0.001, d = 0.80], as well as the anxiety subscale
of the HADS [t (60)=−2.4, p= 0.05, d = 0.30]. No significant
changes were found for the depression subscale of the HADS
[t (60)=−0.6; p= 0.6, d = 0.08], the physical and mental sub-
scales of the SF36 [P : t (60)= 0.8, p= 0.4, d = 0.11; M : t (60)= 0.7,
p= 0.5, d = 0.09], or the VAMS [positive: t (59)=−0.9, p= 0.4,
d = 0.12; negative: t (59)= 0.5, p= 0.6, d = 0.06].
Follow-up
The majority of tests for which a significant treatment effect was
found did not change significantly over the 12-month follow-
up period, indicating that the therapy-induced benefits were
sustained over this period (see Table 2 as well as Figures 1 and 2).
However, a significant decline occurred in MAL-AoU scores
from post to Fup6 [t (33)=−2.4, p= 0.025, d = 0.4], although
the effect size of this decline was not as great as the effect size
of the improvement during therapy (d = 1.19) suggesting that
the amount of affected arm use at 6-month post treatment was
still greater than during the 2-week baseline interval immediately
preceding the intervention. Moreover, the decline did not con-
tinue between Fup6 and Fup12 [t (22)=−0.3, p= 0.8, d = 0.06].
For WMFT-FA scores improved from Fup6 to Fup12 [t (19)= 3.1,
p= 0.007, d = 0.68], but showed no notable change from post
to Fup6 [t (33)= 0.2, p= 0.9, d = 0.03]. Anxiety scores reduced
further from post to Fup6 [t (30)=−2.3, p= 0.032, d = 0.4],
but showed no significant change between Fup6 and Fup12
[t (20)= 1.8, p= 0.084, d = 0.4].
Outcome measures with no significant therapy effects remained
unchanged over the follow-up period (see Table 2), except
for depression scores, which reduced from post to Fup6
[t (19)=−2.9, p= 0.007, d = 0.52] and stayed unchanged Fup6–
Fup12 [t (20)= 0.6, p= 0.6, d = 0.13].
SUB-GROUP ANALYSIS: EFFECTS OF TRAINING INTENSITY AND
CONSTRAINT ON OUTCOME
Treatment effect
For the primary outcome parameters, the ANOVAs revealed a
large effect of TRAINING INTENSITY on NHPT_S [F(1, 62) =
12.7, p = 0.001, η2p = 0.18] and a medium-to-large effect
on MAL AoU [F(1, 64) = 8.3, p = 0.005, η2p = 0.12],
with greater hours of training resulting in greater improvement
(Figure 4). Interactions between TRAINING INTENSITY and
CONSTRAINT were found for NHPT_S [F(1, 62) = 5.9, p =
0.018, η2p = 0.09], MAL AoU [F(1, 64) = 4.9, p = 0.03, η2p =
0.08], and MAL QoM [F(1, 64) = 6.0, p = 0.017, η2p = 0.09],
all with medium effect size. These interactions were due to differ-
ences in TRAINING INTENSITY between the two CONSTRAINT
groups, with greater change observed in patients who wore the
constraint and were in the Tx180C group compared to other treat-
ment groups. None of the other motoric scores showed significant
differences between the treatment groups.
For the secondary outcome parameters, no significant main
effects or interactions were found except for SF36 physical, which
showed greater improvement in patients using a CONSTRAINT
[F(1, 60) = 4.35, p = 0.041, η2p = 0.07], a medium-sized effect,
despite the absence of significant improvement in this scale across
all patients.
Follow-up
Because of substantive drop out, the group size is very small. The
follow-up data for the sub-group comparison are, therefore, too
weak to be fully reported. They are, however, summarized in the
Supplementary Materials. Of note, the treatment effect of those
patients available for follow-up testing and those dropping out
after the post session was not significant for any of the motor
variables or psychological measures.
RELATIONSHIP BETWEEN PRIMARY (MOTOR) AND SECONDARY
(HEALTH/PSYCHOLOGY) PARAMETERS
Regression analysis of treatment effect RCIs revealed that bet-
ter MAL-AoU outcome was significantly associated with better
outcome on general health and psychological wellbeing indices
[F(8,58)= 3.4, p= 0.004]. More specifically, better outcome mea-
sured by MAL AoU was associated with better score on the
SF36 Physical [β= 0.38, t (50)= 2.31, p= 0.025], as well as trend
for SIS Total [β= 0.43, t (50)= 1.92, p= 0.061]. There were no
other significant associations between motoric and non-motoric
outcome.
DISCUSSION
The present study investigated the feasibility and efficacy of the CI
therapy concept in patients with poorer residual recovery, and fur-
ther explored how the two main treatment elements, constraint,
and daily shaping training, affect treatment outcome. In alignment
with CI therapy studies in higher functioning patients, a baseline-
controlled paradigm with 2 weeks of baseline followed by 2 weeks
of intervention was employed. The study was motivated by the
assumption that these treatment elements not only interact with
each other, but that this interaction may also be modulated by the
severity of the motor deficit.
Confirming initial reports (28, 29) that positive outcomes can
be achieved through CI therapy in patients with more severe
hemiparesis, the data obtained through the whole-group analy-
sis provides further and stronger evidence that the CI therapy
approach is feasible and successful in patients with very poorer
www.frontiersin.org October 2014 | Volume 5 | Article 204 | 5
Sterr et al. CI therapy in low-functioning stroke
FIGURE 2 | Average RCI across all participants over the course of therapy
and follow-up. (A) Frenchay Arm Test. (B)Wolf Motor Function Test: Time
Taken (left) and Functional Ability Scale (right). (C) Nine-Hole Peg Test: number
of small pegs (left) and large pegs (right). (D) Motor Activity Log: Amount of
Use (left) and Quality of Movement (right). Error Bars are SEM. ***p<0.001,
**p<0.01, *p<0.05.
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FIGURE 3 | Non-motoric measures across all participants over the course
of therapy and follow-up period. (A) Stroke Impact Scale: total (left) and
physical subscale (right). (B) Short Form 36: physical total (left) and mental
total (right). (C) Hospital Anxiety (left) and Depression (right) Scale. (D) Visual
Analog Mood Score: positive mood (left) and negative mood (right). Error Bars
are SEM. ***p<0.001, **p<0.01, *p<0.05.
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FIGURE 4 | Average RCI for each therapy group over the course of
therapy and follow-up. Tx90/Tx180: 90/180 min’s therapy; nC/C: No
Constraint/With Constraint. (A) Frenchay Arm Test. (B)Wolf Motor Function
Test: Time Taken (left) and Functional Ability Scale (right). (C) Nine-Hole Peg
Test: number of small pegs (left) and large pegs (right). (D) Motor Activity Log:
Amount of Use (left) and Quality of Movement (right). Error Bars are SEM.
***p<0.001, **p< 0.01, *p< 0.05. Probability values indicate an interaction
of treatment or follow-up and either constraint (C) or training intensity (Tx).
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residual recovery. Significant benefits were observed across all
patients on literally all motor outcomes, including those sub-
jectively assessing real-world behavior and those assessing motor
function through formalized tests. Moreover, these benefits were
largely sustained over the 12-month follow-up period. This sug-
gests that the CI therapy variants tested in this study promote
sustained improvements of functional motor skills, and the use
of these skills in everyday life, in patients with minimal ability. In
addition, CI therapy had either positive or neutral effects on the
patients’ wellbeing and mental health. This is an important find-
ing, as it highlights the wider benefits on CI therapy, and further
demonstrates that CI therapy has no adverse effects in patients
with poor recovery.
With regards to the sub-group analysis of the four CI ther-
apy variants tested in this study, the differences in outcome were
relatively small and primarily affected the MAL. More specifi-
cally, using the constraint or having more/less shaping training
did not significantly change the treatment outcome on either scale
of the WMFT, or the FAT. In other words, the treatment ben-
efit indexed by the WMFT subscales, MAL QoM, and FAT was
equally strong in patients who wore the constraint and in those
who did not, and in those who received 180 min of daily training
and 90 min of daily training, respectively. This is an unexpected
finding, not in the least since CI therapy studies on the relationship
between treatment intensity and outcome suggest better outcomes
for longer entities of daily training (13, 30). Furthermore, theo-
retical and empirical evidence on constraining the intact limb in
animals implies that constraining this extremity is necessary to
overcome the learned non-use phenomenon (22, 31), and pro-
motes the implementation of newly learned skills from the therapy
setting into everyday situations (17). This should translate into
better treatment outcome. However, the findings of the present
study do not conform to these assumptions. Rather, they suggest
that only the combination of 180 min of training with the con-
straint produces improved outcome with regard to the subjective
perception of everyday arm use and objective measures of fine fin-
ger movement. For 90 min of training on the other hand, wearing
the constraint did not enhance the treatment benefit. Moreover,
if patients received 180 min of training but did not wear the con-
straint, the treatment benefit was similar to those receiving only
90 min of daily training.
Of course, the findings reported here are based on relatively
small sample sizes (N between 14 an 19 per group), and the
result pattern observed here might be explained by poor test
power. However, if the relative contribution of the constraint
and amount of training were substantive, one would expect to
see significant differences in smaller groups, in particular in
groups with relatively homogenous demographics. The absence
of strong and clear group differences between the CI therapy
variants tested here, therefore, warrants further consideration.
Moreover, the study suffered from substantive drop out and the
notion that CI therapy achieves long-term improvements only
holds for those patients who remained in the sample for the
follow-up period. However, none of the motor or mood vari-
able, or indeed age of chronicity, showed significant differences
between the group of patients completing follow-up sessions
and those dropping out after the post-training assessment. In
addition, this study was conducted in the University and a num-
ber of patients came from far away, and had stayed in rented
accommodation for the therapy session. Returning for a 1/2-day
follow-up session was, therefore, not feasible for many of them.
These logistical into considerations combined with the fact that
no statistical difference existed between those who dropped out
and those who did not indicates that the high drop out rate was
caused by the study characteristics rather than the intervention
per se.
We propose that the lack of substantive differences between
the CI therapy variants might be explained by an interaction
between the treatment mechanisms (constraint/training inten-
sity) and the severity of the motor deficit. Thus, we suggest that
the CI therapy intervention is physically and mentally tiring, and
much more so for patients with minimal recovery. Their lim-
ited physical and cognitive capacity is likely to impact the way
in which they are able to engage with the treatment, and possi-
bly the efficacy of the treatment mechanisms as well. We assume
that if the length of the training session exceeds this capacity,
patients may become too fatigued to fully engage with the inter-
vention. In contrast to high functioning patients, longer training
sessions might therefore not necessarily be more effective than
shorter training sessions in this patient group. On other words, it
might be the case that at least for some patients, the additional
treatment time provided for the 180 min group was rendered inef-
fective because patients had become too fatigued. Moreover, we
speculate that adherence to the constraint condition is particu-
larly challenging in patients with minimal recovery. Patients may
find it difficult to pursue everyday activities when wearing the
constraint and adherence might, therefore, have been quite var-
ied across participants. However, because longer training sessions
provide twice the contact time with the therapist, it might be
that patients in this group could be motivated better to adhere
to the constraint regime than patients with 90 min contact time.
In addition, similar to the vast majority of published CI therapy
studies, the present study captured the amount of time that the
constraint was worn outside the therapy setting through diary
entries. Not all participants completed the diary, and the entries
varied substantively between 1 and 14 h supporting the idea that
constraint adherence is a major factor to be considered in future
studies.
Taken together our data suggest that the CI therapy con-
cept is feasible and can effectively improve motor function in
patients with low-functioning chronic hemiparesis. As such, the
data expand the evidence-base for CI therapy to a wider group
of patients and hence addresses one of the barriers to the clin-
ical implementation of this intervention (5). However, our data
also reveal that the components underpinning CI therapy (con-
straint, training intensity) may have different effects in patients
with more severe hemiparesis. The findings highlight the need to
further characterize the interaction between residual motor abil-
ities and the treatment mechanisms with regards to adherence,
motivation, and, most critically, fatigue. Larger trials that directly
compare shorter and longer training times in conjunction with and
without the constraint are necessary to create the evidence-base
needed to optimize CI therapy for patients with varying degrees
of residual function.
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